Table 4.
Risk factors between baseline PCT, CRP and NLR and death in patients with COVID-19 in the subgroup analysis.
| Laboratory tests | Characteristics | n | Model 0a | Model 1b | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| PCT, ng/mL (≥ 0.10 vs. < 0.1) | Age (< 60y) | 37 | 3.76e+8 (0–Inf) | 0.999 | 84,176.46 (0–Inf) | 0.989 |
| Age (≥ 60y) | 39 | 10.08 (1.29–78.80) | 0.028 | 53.76 (1.02–2,824.88) | 0.049 | |
| Male | 46 | 6.27 (0.79–49.89) | 0.083 | 1.53e+6 (0–Inf) | 0.989 | |
| Female | 30 | 1.28e+9 (0–Inf) | 0.999 | 1.58 (0–Inf) | 0.999 | |
| Severe* | 50 | 7.46 (0.98–56.54) | 0.052 | 39.37 (1.50–1,036.84) | 0.028 | |
| CRP, mg/L (≥ 52.14 vs. < 52.14) | Age (< 60y) | 37 | 4.39 (0.48–39.73) | 0.188 | 2.93e+13 (0–Inf) | 0.990 |
| Age (≥ 60y) | 39 | 23.59 (3.01–185.03) | 0.003 | 14.95 (0.78–287.68) | 0.073 | |
| Male | 46 | 6.37 (1.29–31.41) | 0.023 | 2.29e+16 (0–Inf) | 0.998 | |
| Female | 30 | 3.06e+9 (0–Inf) | 0.999 | 8.17e+20 (0–Inf) | 0.948 | |
| Severe* | 50 | 5.54 (1.26–24.28) | 0.023 | 4.72 (0.91–24.56) | 0.065 | |
| NLR (≥ 3.59 vs. < 3.59) | Age (< 60y) | 37 | 3.38e+8 (0–Inf) | 0.999 | 3.57e+8 (0–Inf) | 0.998 |
| Age (≥ 60y) | 39 | 5.92 (0.74–47.58) | 0.094 | 0 (0–Inf) | 0.960 | |
| Male | 46 | 3.56e+8 (0–Inf) | 0.998 | 2.56e+8 (0–Inf) | 0.999 | |
| Female | 30 | 3.38 (0.4–28.28) | 0.261 | 0 (0–Inf) | 0.960 | |
| Severe* | 50 | 0.81 (0.1–6.58) | 0.841 | 3.47 (0.43–28.14) | 0.244 | |
Data in bold indicate values of statistical significance.
COVID-19 coronavirus disease 2019, HR hazard ratio, 95% CI confidence interval, PCT procalcitonin, CRP C-reaction protein, NLR neutrophil-to-lymphocyte ratio.
aModel 0 was unadjusted.
bModel 1 was adjusted for cancer, ARDS, hypohepatia, renal insufficiency, heart failure and shock.
*Severe included critical severe and severe clinical types.